Gilead Sciences Balance Sheet Health
Financial Health criteria checks 3/6
Gilead Sciences has a total shareholder equity of $18.4B and total debt of $23.2B, which brings its debt-to-equity ratio to 126.4%. Its total assets and total liabilities are $54.5B and $36.1B respectively. Gilead Sciences's EBIT is $11.2B making its interest coverage ratio 16.4. It has cash and short-term investments of $6.7B.
Key information
126.4%
Debt to equity ratio
US$23.25b
Debt
| Interest coverage ratio | 16.4x |
| Cash | US$6.70b |
| Equity | US$18.39b |
| Total liabilities | US$36.13b |
| Total assets | US$54.53b |
Recent financial health updates
Recent updates
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Dec 18Gilead Sciences, Inc.'s (NASDAQ:GILD) Business And Shares Still Trailing The Industry
Dec 13
We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings
Nov 13Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Nov 07Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It
Oct 01Gilead Sciences: Buy This Bargain Before It's Gone
Aug 30Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?
Aug 05A Look At Gilead Sciences After Its Recent Weakness
Jul 27Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
May 23We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation
May 02Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark
Apr 22Gilead Sciences: Some Signs Of An Impending Bottom
Apr 22Financial Position Analysis
Short Term Liabilities: GILD's short term assets ($14.8B) exceed its short term liabilities ($11.7B).
Long Term Liabilities: GILD's short term assets ($14.8B) do not cover its long term liabilities ($24.4B).
Debt to Equity History and Analysis
Debt Level: GILD's net debt to equity ratio (90%) is considered high.
Reducing Debt: GILD's debt to equity ratio has increased from 118.6% to 126.4% over the past 5 years.
Debt Coverage: GILD's debt is well covered by operating cash flow (43.1%).
Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (16.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gilead Sciences, Inc. is covered by 75 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |